Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system disorders, for about $14.6 billion.

Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system disorders, for about $14.6 billion. J&J will pay $132 a share, the company said in a statement. That’s 39% above the closing price on Friday. Bloomberg earlier reported a deal was in the works.

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for major depressive disorder.

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies, a company specialising in central nervous system disorder treatments, as reported by Bloomberg. The deal could be finalised as early as mid-January 2025, although the confidential talks may not necessarily result in an agreement.

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments. J&J will buy all of Intra-Cellular's shares for $132 apiece,